S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
The single greatest medical breakthrough of all time? (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The single greatest medical breakthrough of all time? (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
The single greatest medical breakthrough of all time? (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The single greatest medical breakthrough of all time? (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
The single greatest medical breakthrough of all time? (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The single greatest medical breakthrough of all time? (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
The single greatest medical breakthrough of all time? (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The single greatest medical breakthrough of all time? (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:NYMX

Nymox Pharmaceutical (NYMX) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.19
▼
$0.47
52-Week Range
N/A
Volume
932,700 shs
Average Volume
94,622 shs
Market Capitalization
$18.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

NYMX stock logo

About Nymox Pharmaceutical (NASDAQ:NYMX) Stock

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.


NYMX Stock News Headlines

August 29, 2023 | markets.businessinsider.com
Nymox Reports Completion of $2 Million Private Placement
July 18, 2023 | finanznachrichten.de
Nymox Pharmaceutical Corporation: Nymox Reports on U.S. Patent Issuances
September 24, 2023 | Legacy Research (Ad)
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
July 18, 2023 | finance.yahoo.com
Nymox Reports on U.S. Patent Issuances
July 16, 2023 | venturebeat.com
The Committee to Restore Nymox Shareholder Value Soundly Rebuts Injurious Allegations Made by Nymox Pharmaceutical Corp Current Management
July 12, 2023 | finance.yahoo.com
Nymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of Nymox
July 9, 2023 | venturebeat.com
Rebuttal Letters Issued to Shareholders of NYMOX PHARMACEUTICAL CORP (“NYMX-Q”)
July 8, 2023 | finanznachrichten.de
Nymox Pharmaceutical Corporation: NYMOX Update
September 24, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
July 7, 2023 | financialpost.com
NYMOX Update
July 6, 2023 | investorplace.com
Why Is Nymox Pharmaceutical (NYMX) Stock Down 18% Today?
July 6, 2023 | seekingalpha.com
Nymox Pharmaceutical receives potential delisting notice from Nasdaq
July 6, 2023 | msn.com
NYMX Tanks after Receiving Delisting Notice
July 5, 2023 | financialpost.com
Nymox Delisting from NASDAQ
June 30, 2023 | finance.yahoo.com
NYMX - Nymox Pharmaceutical Corporation
June 28, 2023 | thestreet.com
Nymox Pharmaceutical (NYMX) Stock Down After Disappointing Enlarged Prostate Treatment Test Results
June 15, 2023 | fool.com
Nymox Pharmaceutical (NASDAQ: NYMX)
May 10, 2023 | finanznachrichten.de
Nymox Pharmaceutical Corporation: Nymox Provides Current Update
April 3, 2023 | finance.yahoo.com
Nymox Provides Corporate Update
March 21, 2023 | finance.yahoo.com
Nymox Announces Appointment of Christopher R. Riley as Chief Financial Officer
March 15, 2023 | finance.yahoo.com
Nymox Officially Granted Extension to Regain Listing Requirements
March 6, 2023 | finance.yahoo.com
One Nymox Pharmaceutical Corporation (NASDAQ:NYMX) insider upped their stake by 32% in the previous year
February 15, 2023 | finance.yahoo.com
Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review
January 6, 2023 | finance.yahoo.com
NYMOX Appeals Deficiency Letter
December 5, 2022 | finance.yahoo.com
NYMOX Announces New Marketing Submission for NYMOZARFEX™ for BPH
November 25, 2022 | financialpost.com
May 2023 Market Cap Requirement Update
September 27, 2022 | finance.yahoo.com
A Nymox Pharmaceutical Corporation (NASDAQ:NYMX) insider increased their holdings by 32% last year
See More Headlines
Receive NYMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

NYMX Company Calendar

Last Earnings
11/14/2014
Today
9/24/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NYMX
CUSIP
N/A
CIK
1018735
Web
www.nymox.com
Phone
(800) 936-9669
Fax
514-332-2227
Employees
3
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,580,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,589.50%
Return on Assets
-117.25%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.19
Quick Ratio
0.19

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.01) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
90,510,000
Free Float
41,637,000
Market Cap
$18.10 million
Optionable
Optionable
Beta
0.64
10 Best Stocks to Own in 2023 Cover
10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Paul Averback DABP (Age 72)
    M.D., Founder, Chairman, CEO & Pres
    Comp: $660k
  • Mr. Randall J. Lanham Esq. (Age 59)
    J.D., Gen. Counsel, Sec., COO & Director
    Comp: $496.45k
  • Ms. Lin Dodd
    QA and Compliance Mang.
  • Mr. Christopher R. Riley
    Chief Financial Officer

Key Competitors

View All Competitors













NYMX Stock - Frequently Asked Questions

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Co. (NASDAQ:NYMX) released its quarterly earnings data on Friday, November, 14th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The biopharmaceutical company had revenue of $0.08 million for the quarter.

What other stocks do shareholders of Nymox Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and CTI BioPharma (CTIC).

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

How much money does Nymox Pharmaceutical make?

Nymox Pharmaceutical (NASDAQ:NYMX) has a market capitalization of $0.00. The biopharmaceutical company earns $-6,580,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis.

How can I contact Nymox Pharmaceutical?

Nymox Pharmaceutical's mailing address is BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2. The official website for the company is www.nymox.com. The biopharmaceutical company can be reached via phone at (800) 936-9669, via email at info@nymox.com, or via fax at 514-332-2227.

This page (NASDAQ:NYMX) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -